Effect of actinomycin D on Paget's disease of bone.
Four patients with active Paget's disease were treated with the RNA inhibitor actinomycin D. Three were clinically improved after treatment; the fourth had multiple collapsed vertebrae and showed no symptomatic improvement. Striking changes took place in urinary calcium and hydroxyproline, in serum alkaline phosphatase, and to a less extent in serum calcium and phosphate. These studies are continuing and are being compared with the effects of mithramycin.
D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D002118:Calcium / Q000097:blood / Q000652:urine; D003609:Dactinomycin / Q000009:adverse effects / Q000627:therapeutic use*; D003863:Depression / Q000139:chemically induced; D006801:Humans
D003609:Dactinomycin; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; D002118:Calcium